Holen Sie sich die Stockscreener-App
319.14
0.23%
-0.73
Vorhandelsmarkt:
319.20
0.06
+0.02%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SYK?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$319.87
Offen:
$319.23
24-Stunden-Volumen:
1.58M
Relative Volume:
0.59
Marktkapitalisierung:
$122.35B
Einnahmen:
$25.27B
Nettoeinkommen (Verlust:
$3.34B
KGV:
36.97
EPS:
8.6334
Netto-Cashflow:
$4.57B
1W Leistung:
-3.71%
1M Leistung:
+3.68%
6M Leistung:
-11.25%
1J Leistung:
-18.04%
1-Tages-Spanne:
$317.19
$322.16
1-Wochen-Bereich:
$306.53
$335.86
52-Wochen-Spanne:
$281.00
$404.14
Stryker Corp Stock (SYK) Company Profile
Firmenname
Stryker Corp
Sektor
Branche
Telefon
(269) 385-2600
Adresse
1941 STRYKER WAY, PORTAGE, MI
Compare SYK vs ABT, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYK
Stryker Corp
|
319.14 | 122.35B | 25.27B | 3.34B | 4.57B | 8.6334 |
ABT
Abbott Laboratories
|
101.66 | 177.07B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
83.29 | 106.61B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
43.77 | 65.06B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.00 | 48.94B | 6.30B | 1.07B | 1.09B | 1.8406 |
Stryker Corp Stock (SYK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Eingeleitet | Leerink Partners | Outperform |
| 2026-02-20 | Eingeleitet | William Blair | Outperform |
| 2026-01-27 | Fortgesetzt | TD Cowen | Hold |
| 2026-01-06 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2025-12-19 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-09-18 | Eingeleitet | Rothschild & Co Redburn | Neutral |
| 2025-02-26 | Fortgesetzt | Citigroup | Buy |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-10 | Eingeleitet | Wolfe Research | Outperform |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-22 | Hochstufung | Needham | Hold → Buy |
| 2024-01-31 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-10-20 | Eingeleitet | ROTH MKM | Buy |
| 2023-09-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-25 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2023-01-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-11-01 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-28 | Hochstufung | Edward Jones | Hold → Buy |
| 2022-07-21 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-07-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-04-13 | Eingeleitet | Truist | Hold |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-15 | Fortgesetzt | Evercore ISI | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-12-07 | Eingeleitet | Loop Capital | Buy |
| 2021-09-14 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-07-28 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2021-06-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Underweight |
| 2020-10-06 | Eingeleitet | Northland Capital | Market Perform |
| 2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-04-13 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2020-04-01 | Herabstufung | Goldman | Buy → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-08 | Eingeleitet | SunTrust | Hold |
| 2020-01-07 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2020-01-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2019-12-30 | Bestätigt | BTIG Research | Buy |
| 2019-11-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-10-30 | Bestätigt | BofA/Merrill | Buy |
| 2019-07-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-01-30 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Buy |
| 2019-01-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-08-16 | Eingeleitet | BTIG Research | Buy |
| 2018-06-27 | Eingeleitet | Bernstein | Mkt Perform |
| 2018-04-27 | Bestätigt | Stifel | Buy |
Alle ansehen
Stryker Corp Aktie (SYK) Neueste Nachrichten
Stryker stock builds on earnings momentum after 16 July 2026 update - Ad-hoc-news.de
Stryker stock trades on its latest reported growth - ad-hoc-news.de
Mako Handheld Robotic Knee System Launch Might Change The Case For Investing In Stryker (SYK) - Yahoo Finance
Is Stryker Corp (SYK) a Bargain After 3.4% Drop? GF Value Says U - GuruFocus
Stryker Corp. stock underperforms Friday when compared to competitors - MarketWatch
Stryker Corp Stock (SYK) Moved Down by 3.42% on Jul 17: A Full Analysis - TradingKey
Stryker stock trades near highs as robotics and trauma growth support valuation - ad-hoc-news.de
Stryker Launches Mako RPS to Expand Robotic Knee Surgery Portfolio - The Globe and Mail
Stryker Corp (XTER:SYK) Stock Price, Trades & News - GuruFocus
Stryker Corp. stock outperforms competitors on strong trading day - MarketWatch
Stryker (SYK) Launches Mako RPS Handheld Robot for Knee Replacem - GuruFocus
Stryker Shares Rise After Commercial Launch of Mako Robotic Power System - Moomoo
Stryker (SYK) Introduces Mako RPS for Total Knee Replacements - GuruFocus
Stryker launches Mako RPS handheld robotic knee system in U.S. - Investing.com
Stryker expands Mako robotics portfolio with full market release of Mako RPS - Finviz
Stryker Reports More Than 2.5M Mako Procedures in 47 Countries - Stock Titan
Stryker's quarterly earnings preview: What you need to know - MSN
Stryker Corp. stock underperforms Tuesday when compared to competitors - MSN
Stryker Corp (SYK) Stock Down 6.2% -- Now Undervalued? GF Score: 92/100 - GuruFocus
Goldman Sachs Adjusts Price Target on Stryker to $339 From $363, Maintains Neutral Rating - Moomoo
Stryker Corp Stock (SYK) Moved Down by 5.49% on Jul 14: A Full Analysis - TradingKey
Fund Update: 43,404 STRYKER (SYK) shares added to Douglas Lane & Associates, LLC portfolio - Quiver Quantitative
Stryker Slides As Investors Reassess Cyberattack Recovery Ahead Of Q2 Results - Quiver Quantitative
RBC Capital Maintains Stryker Corp(SYK.US) With Buy Rating, Maintains Target Price $435 - Moomoo
BTIG Research Adjusts Stryker Price Target to $371 From $379, Maintains Buy Rating - Moomoo
Disposable Endoscopes Market Size Projected to Hit USD 10.47 Billion by 2035 | SNS Insider - GlobeNewswire Inc.
Piper Sandler reiterates Stryker stock rating on Mako strength - Investing.com
Piper Sandler reiterates Stryker stock rating on Mako strength By Investing.com - Investing.com Canada
Stryker Corp Stock Operating Data - GuruFocus
Stryker Corp (FRA:SYK0) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Stryker (FRA:SYK0) Interest Paid - GuruFocus
Stryker Corp (FRA:SYK0) Competitors 2026 - GuruFocus
Stryker Corp (FRA:SYK0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Stryker Corp (FRA:SYK0) Stock Price & 30 Year Financial Data - GuruFocus
Stryker Corp (FRA:SYK0) Valuation: Modestly Undervalued - GuruFocus
FRA:SYK0 Dividend: Does Stryker Corp Pay a Dividend? - GuruFocus
Stryker Corp (FRA:SYK0) Stock Earnings Transcripts - GuruFocus
Stryker Corp Stock Warning Signs - GuruFocus
Who's Buying or Selling Stryker Corp (FRA:SYK0) Stock Today? - GuruFocus
Stryker Corp (FRA:SYK0) Stock News, Headlines & Updates - GuruFocus
Argus raises Stryker stock price target on cyberattack recovery By Investing.com - Investing.com Australia
Argus raises Stryker stock price target on cyberattack recovery - Investing.com
Inside medtech’s cameo run on HBO Max’s ‘The Pitt’ - Modern Healthcare
Argus Research Maintains Stryker Corp(SYK.US) With Buy Rating, Cuts Target Price to $370 - Moomoo
Stryker's Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
Mixed Drivers Fuel Optimism in Stryker Corporation’s (SYK) Performance - Insider Monkey
SYK Initiates Coverage On Stryker -- Price Target Announced at $369 - GuruFocus
Argus Research Adjusts Stryker Price Target to $370 From $350 - Moomoo
Global Orthopedic Surgical Robots Market Report Published — Profiles Stryker, Zimmer Biomet, DePuy Synthes, and Medtronic - Yahoo Finance
Stryker Corp. focuses on innovation as medical device demand grows - AD HOC NEWS
Citi Maintains Stryker Corp(SYK.US) With Buy Rating, Maintains Target Price $385 - Moomoo
Finanzdaten der Stryker Corp-Aktie (SYK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):